Chemotherapy Research and Practice

Review Article

Lipoplatin Treatment in Lung and Breast Cancer

Table 1

phase I and II studies with lipoplatin.


Author	Chemotherapeutic schema	Study phase	Diseases	Pts N°	Line	OR%	SD%	mTTP	mOS

Stathopoulos et al. [2]	Lipoplatin 25–125 mg/every 2 weeks	Phase I	Various	27	2nd-3rd	11.1%	51.9%

Froudarakis et al. [3]	Lipoplatin 100–130 mg/m² days 1 and 8, Gemcitabine 1000 mg/m² days 1 and 8 q 21 days	Phase I	NSCLC	13	2nd -3rd	7.6%	15.4%	12 w	29 w

Stathopoulos et al. [4]	Gemcitabine 1000 mg/m² and Lipoplatin 25–125 mg/m² administered as an 8 h i.v. infusion on days 1 and 15, and cycles were repeated every 4 weeks (28 days)	Phase I-II	Pancreatic cancer	24	2nd	8.3%	58.3%		4 m

Ravaioli et al.[5]	Lipoplatin at 100 mg/m² on days 1, 14 in combination with gemcitabine 1000 mg/m² on days 1, 8 in a 28-day cycle	Phase I-II	Various	38	2nd -3rd	23%	65.3%

Anevlavis et al. [6]	Lipoplatin 100 mg/m² on day 1 in a 14-day cycle	Phase II	NSCLC	19	2nd	5.2%	15.9%

Mylonakis et al. [7]	Lipoplatin 120 mg/m² days 1 and 8 plus gemcitabine 1000 mg/m² days 1 and 8 every 3 weeks	Phase II	NSCLC	27	2nd cisplatin refractory	22.2%	18.5%

Farhat et al. [8]	Lipoplatin120 mg/m² (days 1, 8 and 15) and gemcitabine 1000 mg/m² (days 1 and 8) q21-day	Randomized Phase II	NSCLC	47	1st	31.7%	39%

	Lipoplatin 120 mg/m² (days 1, 8 and 15) and gemcitabine 1000 mg/m² (days 1 and 8) q21-days	Randomized Phase II	NSCLC	41	1st	25.6%	30.8%

Koukourakis et al. [9]	Vinorelbine 30 mg/m² on (days 1 and 8) while Lipoplatin was administered at the dose of 120 mg/m² on days 1, 8 and 15 q 21d	Phase II	MBC	35		53%	36.7%

Jehn et al. [10]	Lipoplatin 120 mg/m², 5-FU at 400 mg/m² (day 1), radiotherapy 3.5 Gy fractions on days 2, 3, and 4 in a 7-day schedule	Phase II	Gastric cancer	6 (4 cycles)	1st-line LAD	83%
				6 (5 cycles)		80%